- Trials with a EudraCT protocol (1,640)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (3)
1,640 result(s) found for: Fasting.
Displaying page 1 of 82.
EudraCT Number: 2013-005043-86 | Sponsor Protocol Number: 1308143 | Start Date*: 2014-03-21 | |||||||||||
Sponsor Name:CHU de Saint-Etienne | |||||||||||||
Full Title: Reactivity of the autonomic nervous system after a nociceptive stress in the newborn: Interest of sucrose and non-nutritive sucking. | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002192-19 | Sponsor Protocol Number: ISIS678354-CS5 | Start Date*: 2022-07-22 | ||||||||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia | ||||||||||||||||||
Medical condition: Severe hypertryglyceridemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Trial now transitioned) NO (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) HU (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) FI (Trial now transitioned) BG (Trial now transitioned) SK (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-004497-40 | Sponsor Protocol Number: METIGT2008 | Start Date*: 2008-11-11 | |||||||||||
Sponsor Name:Hull and East Yorkshire Hospitals NHS Trust | |||||||||||||
Full Title: The effect of metformin on weight and cardiovascular risk markers in abdomenally obese subjects with impaired fasting glucose previously treated for 12 months with either rimonabant or placebo | |||||||||||||
Medical condition: Impaired fasting glucose | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005445-16 | Sponsor Protocol Number: NL74623.078.20 | Start Date*: 2021-02-23 |
Sponsor Name:Erasmus MC, University Medical Center Rotterdam | ||
Full Title: Fasting before live kidney donation, effect on donor wellbeing and postoperative recovery | ||
Medical condition: Preoperative fasting in combination with a low-dose laxative and postoperative recovery and complications in living kidney donors | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-002421-35 | Sponsor Protocol Number: ISIS304801-CS6 | Start Date*: 2014-10-27 | ||||||||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS) | ||||||||||||||||||
Medical condition: Familial Chylomicronemia Syndrome (FCS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) DE (Completed) IT (Completed) HU (Completed) ES (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-002536-67 | Sponsor Protocol Number: ISIS678354-CS3 | Start Date*: 2021-04-15 | ||||||||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of AKCEA‑APOCIII‑LRX Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS) | ||||||||||||||||||
Medical condition: Familial Chylomicronemia Syndrome (FCS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) SE (Completed) NO (Completed) FR (Completed) PT (Completed) SK (Completed) HU (Completed) NL (Ongoing) ES (Ongoing) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-005535-68 | Sponsor Protocol Number: CLCQ908B2302 | Start Date*: 2012-05-08 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, placebo controlled study to assess efficacy, safety and tolerability of LCQ908 in subjects with Familial Chylomicronemia Syndrome | |||||||||||||
Medical condition: Familial Chylomicronemia Syndrome (FCS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003280-95 | Sponsor Protocol Number: ISIS678354-CS13 | Start Date*: 2022-06-16 | ||||||||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: An Open-Label Extension Study of AKCEA-APOCIII-LRX Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS) | ||||||||||||||||||
Medical condition: Familial Chylomicronemia Syndrome (FCS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) NL (Trial now transitioned) NO (Completed) PT (Trial now transitioned) FR (Trial now transitioned) SK (Trial now transitioned) IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003755-21 | Sponsor Protocol Number: ISIS304801-CS7 | Start Date*: 2016-06-06 | ||||||||||||||||
Sponsor Name:Akcea Therapeutics | ||||||||||||||||||
Full Title: An Open-Label Study of Volanesorsen Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS) | ||||||||||||||||||
Medical condition: Familial Chylomicronemia Syndrome (FCS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) NL (Completed) ES (Completed) DE (Completed) FR (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-005499-41 | Sponsor Protocol Number: CLAF237A2411 | Start Date*: 2012-12-05 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A double blind, double dummy, randomised, multi-centre study to assess the tolerability and efficacy profile of vildagliptin compared to gliclazide as dual therapy with metformin in Muslim patients... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) ES (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005064-22 | Sponsor Protocol Number: TA-8995-301 | Start Date*: 2022-09-22 | ||||||||||||||||
Sponsor Name:NewAmsterdam Pharma B.V. | ||||||||||||||||||
Full Title: Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies (BROOKLYN): A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Partici... | ||||||||||||||||||
Medical condition: dyslipidemia heterozygous familial hypercholesterolemia (HeFH) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) NL (Completed) CZ (Completed) PL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003434-93 | Sponsor Protocol Number: ISIS-304801-CS16 | Start Date*: 2015-01-07 | |||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients with Hypertriglyceridemia | |||||||||||||
Medical condition: Hypertriglyceridemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Ongoing) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001441-24 | Sponsor Protocol Number: CUI_001 | Start Date*: 2014-08-08 |
Sponsor Name:Medical University Innsbruck | ||
Full Title: Short-term effect of SGLT 2-inhibitor dapagliflozin on postprandial glucose excursion and insulin sensitivity in type 1 diabetic patients. | ||
Medical condition: effects of Dapagliflozin on postprandial glucose excursion and fasting glucose homeostasis | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-000493-35 | Sponsor Protocol Number: ISIS-304801-CS17 | Start Date*: 2016-02-17 | |||||||||||
Sponsor Name:Akcea Therapeutics, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, with an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients with Familial Partial Lipodystrophy | |||||||||||||
Medical condition: Partial lipodystrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) BE (Completed) PT (Prematurely Ended) ES (Completed) NL (Completed) GR (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000179-17 | Sponsor Protocol Number: ikfe-Lina-002 | Start Date*: 2012-04-02 | |||||||||||
Sponsor Name:ikfe GmbH | |||||||||||||
Full Title: Effect of Linagliptin in comparison with Glimepiride as add on to Metformin on postprandial beta cell function, postprandial metabolism and oxidative stress in patients with type 2 diabetes mellitus | |||||||||||||
Medical condition: Diabetes mellitus type 2 on metformin therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016382-29 | Sponsor Protocol Number: P1736-05/34/09 | Start Date*: 2009-11-06 |
Sponsor Name:Piramal Life Sciences Limited | ||
Full Title: A Phase II, 12-Week Randomised, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate Safety, Tolerability, Pharmacokinetics and Effect On Glycemic Control of P1736-05 in Subjects wi... | ||
Medical condition: Diabetes mellitus, type 2 (Blood Glucose Lowering Effect)/ | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) HU (Completed) CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-002643-28 | Sponsor Protocol Number: B1481020 | Start Date*: 2013-12-10 | ||||||||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | ||||||||||||||||||
Full Title: A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, LONG-TERM SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXE... | ||||||||||||||||||
Medical condition: primary hyperlipidemia or mixed dyslipidemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: LT (Completed) GB (Completed) ES (Completed) HU (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-002217-22 | Sponsor Protocol Number: SJ-546 | Start Date*: 2016-09-02 | ||||||||||||||||
Sponsor Name:Sjællands University Hospital, Køge | ||||||||||||||||||
Full Title: Validation of stimulated ∆FGF19 for diagnosing bile acid diarrhoea | ||||||||||||||||||
Medical condition: Bile acid malabsorption / bile acid diarrhoea | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-002425-34 | Sponsor Protocol Number: T160/2018 | Start Date*: 2019-09-06 | |||||||||||
Sponsor Name:Turku University Hospital | |||||||||||||
Full Title: LIRAGLUTIDE IN THE PREVENTION OF T2DM AFTER GESTATIONAL DIABETES | |||||||||||||
Medical condition: Type 2 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000940-28 | Sponsor Protocol Number: Final Protocol version 6 | Start Date*: 2007-11-28 | ||||||||||||||||
Sponsor Name:University Hospitals of Leicester NHS Trust | ||||||||||||||||||
Full Title: The Rimonabant in treatment of Prediabetes Study: a randomised clinical trial of Rimonabant in the treatment of patients with Prediabetes | ||||||||||||||||||
Medical condition: Impaired Glucose tolerance and Impaired fasting Glycaemia (Together known as Prediabetes) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
